Innovative Pharmacological Approaches in Targeting Drug Resistance Mechanisms: A Biomedicine Perspective

Dewi Pangestuti[1], Nanda Novziransyah[2]

[1]*Universitas Islam Sumatera Utara, Indonesia, dewi.pangestuti@fk.uisu.ac.id, https://orcid.org/0009-0007-5317-7861*
[2]*Universitas Islam Sumatera Utara, Indonesia, nanda_novziransyah@fk.uisu.ac.id, https://orcid.org/0000-0003-1987-6611*
Ira Aini Dania, *Universitas Islam Sumatera Utara, Indonesia, ira_aini@fk.uisu.ac.id, https://orcid.org/0000-0002-7534-337X*

KEYWORDS
Drug resistance, innovative pharmacology, combination therapy, nanotechnology, gene therapy.

ABSTRACT:

Introduction: Drug resistance is a major challenge in the treatment of infectious diseases and cancer. Complex drug resistance mechanisms, such as changes in molecular targets, increased drug effusion, and DNA repair mechanisms, hamper the effectiveness of conventional therapies.

Objectives: This study aims to identify innovative pharmacological approaches that can overcome drug resistance.

Methods: This study uses a qualitative method with a descriptive-analytical approach, which aims to explore in depth innovative pharmacological approaches in targeting drug resistance mechanisms. Qualitative methods were chosen because they allow for a more in-depth understanding of the phenomenon of drug resistance from a biomedical perspective, as well as providing space to identify and explain important findings that could lead to innovations in drug therapy.

Results: This study explored nanotechnology-based strategies, combination therapy, the use of specific inhibitors, as well as gene therapy-based approaches. The results show that these strategies have the potential to improve therapeutic effectiveness by targeting specific resistance mechanisms.

Conclusions: Innovative pharmacological approaches, such as nanotechnology, combination therapy and gene therapy, offer promising solutions to overcome drug resistance mechanisms. Further research is needed to test the effectiveness and safety of these strategies on a clinical scale.

1. Introduction

Drug resistance represents one of the most significant health challenges of the 21st century, impacting the management of numerous diseases, including bacterial, viral and parasitic infections, as well as cancer (Roszkowska, 2024). Resistance arises when pathogens or abnormal cells evolve mechanisms that render them unresponsive to previously efficacious treatments. This phenomenon not only elevates morbidity and mortality but also precipitates a surge in healthcare expenditures due to the necessity for more sophisticated or intricate therapeutic regimens (Mao et al., 2024).

The emergence of drug resistance is the result of a multitude of biological mechanisms that evolve in response to selective pressure exerted by the use of pharmaceutical agents, whether directly or indirectly (Trauner et al., 2014). The following are the primary contributing factors:

Genetic mutations are a significant contributing factor to the emergence of drug resistance.

Spontaneous mutations in a drug target gene can result in a reduction in the affinity of the drug to that target. An example of this is antibiotic resistance through gene mutations in bacterial ribosomes, which alter the structure of the ribosome, preventing the binding of antibiotics (Ye & Sun, 2024).

In the context of cancer, mutations of genes such as EGFR, KRAS, or TP53 frequently result in cancer cells becoming resistant to therapies that are designed to target specific pathways.

Microorganisms or cancer cells may increase the production of enzymes that break down or inactivate drugs. For example, the enzyme beta-lactamase, which is found in bacteria, breaks down beta-lactam antibiotics (M, 2024).

In the context of cancer, the increased expression of effusion pumps such as P-glycoprotein (P-gp) enables cancer cells to remove drugs from the cytoplasm prior to their reaching their intended target.

In the event of a disruption to the metabolic pathway that a drug is targeting, pathogens or cancer cells may shift their activity to other pathways in order to maintain vital functions. For instance, cancer cells that depend on glycolysis may utilise fatty acid oxidation as an alternative energy source (H. Lee et al., 2022).

Horizontal genetic transfer is the transfer of genetic material between organisms that are not related by a direct lineage.

In microorganisms, resistance is frequently disseminated through horizontal genetic transfer, such as the transfer of plasmids carrying resistance genes between bacteria.

Conventional medicine frequently employs monotherapy, which is the administration of a single pharmacological agent to treat a given disease (Chen et al., 2024). While monotherapy may initially prove effective, this approach is ultimately flawed due to several significant limitations.

Single Selection Pressure: The application of monotherapy exerts a single selection pressure on microorganisms or cancer cells, thereby promoting the emergence of resistant populations that have a selective advantage (Li & Ma, 2024).

A further limitation of monotherapy is the lack of multiple mechanism targeting. Monotherapies typically target a single biological mechanism, thereby allowing pathogens or cancer cells to develop resistance through alternative mechanisms that are not affected by the drug.

Inappropriate Use: The utilisation of pharmaceutical agents that are not optimally dosed or administered for an appropriate duration frequently precipitates the emergence of resistance. This phenomenon can be observed in instances of overuse or premature cessation of antibiotic therapy (Pemathilaka et al., 2022).

In order to address the issue of complex and multifactorial drug resistance, it is necessary to implement innovative approaches that focus on targeting specific mechanisms of resistance. These strategies often involve multidisciplinary approaches and can be broadly categorised as follows:

Combination therapy represents a promising avenue for addressing complex and multifactorial drug resistance. This approach involves the use of two or more drugs that act through different mechanisms, thereby reducing the likelihood of resistance. An illustrative example is HAART (Highly Active Antiretroviral Therapy) for HIV, which effectively inhibits multiple steps in the virus' life cycle (Jin et al., 2024).

The use of two or more drugs that act through different mechanisms can reduce the likelihood of resistance. These combinations can include both the main drug and inhibitors of resistance mechanisms. An example is HAART (Highly Active Antiretroviral Therapy) therapy for HIV, which successfully inhibits several steps in the virus' life cycle (Martina et al., 2024).

Nanoparticles are employed to circumvent drug effusion or enhance bioavailability. This technology enables drugs to reach more precise targets and reduce exposure to healthy tissues, thereby reducing the risk of resistance.

The development of small molecule inhibitors that target specific proteins or enzymes has yielded encouraging outcomes. For instance, tyrosine kinase inhibitors (TKIs) such as imatinib are employed in the treatment of chronic myeloid leukaemia (CML) (Jones et al., 2024).

Techniques such as CRISPR-Cas9 permit the modification of genes implicated in drug resistance. This approach can directly inactivate genes that contribute to resistance or correct genetic mutations.

In order to combat antibiotic resistance, it is possible to improve the balance of the gut microbiota, which will in turn suppress the population of pathogenic bacteria (Liu et al., 2024).

The investigation of molecules that inhibit effusion pumps, such as P-glycoproteins, may facilitate the enhancement of pharmacological efficacy by preventing the expulsion of drugs from target cells.

2. Objectives

The objective of this research is to contribute to the understanding and development of innovative pharmacological strategies that can overcome the challenges of drug resistance, both in the context of infectious diseases and cancer. Drug resistance has become one of the most significant obstacles in modern medicine, causing increased morbidity and mortality worldwide (Queffeulou et al., 2024). Consequently, this study focuses on several specific objectives, which are described in detail below:

Identification of the principal mechanisms of drug resistance

The principal objective of this research is to delineate the primary mechanisms that underpin drug resistance. The mechanisms under investigation include:

Genetic Mutations: The identification of mutated genes that result in alterations to molecular targets in microorganisms or cancer cells (Markalunas et al., 2024).

The increased expression of effusion transporters is a process whereby transporter proteins, such as P-glycoprotein, expel drugs from cells, thereby lowering the intracellular concentration of drugs.

The objective is to elucidate the DNA repair mechanisms that safeguard cancer cells from the effects of drugs (J. Lee et al., 2024).

Enzyme-Mediated Drug Metabolism: This area of research evaluates the role of enzymes such as cytochrome P450 in the metabolism of drugs and the subsequent reduction in their effectiveness.

The objective of this research is to integrate data from a range of studies in order to gain a comprehensive understanding of the molecular and biochemical processes involved in the development of drug resistance.

Investigation of Innovative Pharmacological Approaches

The subsequent objective is to assess the potential of novel approaches to circumvent drug resistance, including:

Nanotechnology strategies: An investigation of the potential of nanoparticles, including liposomes, dendrimers and metal nanoparticles, as a means of improving the specificity and efficiency of drug distribution to target tissues (Litty, 2024).

Combination Therapy: An investigation of the potential for drug combinations, including antibiotics with effusion inhibitors, to overcome resistance by harnessing the synergistic effects between molecules (Cummings et al., 2024).

Specific Molecular Inhibitors: An evaluation of the potential of target inhibitors, such as kinase inhibitors in cancer or beta-lactamase inhibitors in bacterial infections, is required.

Gene therapy: An examination of the potential of technologies such as CRISPR-Cas9 and RNAi to modify resistance genes, with a view to providing long-term solutions for disease treatment.

It is anticipated that these approaches will facilitate the development of more efficacious treatments, particularly for instances of resistance that are challenging to address with conventional therapeutic modalities.

Linking Pharmacological Strategies with Clinical Implications

Another objective is to facilitate the translation of research results in pharmacology and biomedicine into real clinical applications (Gupta & Bhandari, 2024). This research aims to address the following questions:

The objective is to ascertain how these innovative approaches can be integrated into clinical practice.

What are the potential challenges to implementation, such as those related to safety, cost, and technology availability?

The objective is to ascertain how these strategies can be tailored to the treatment of patients with specific conditions, such as multidrug resistance (RAVAL et al., 2024).

Facilitating the Development of Future Drugs

The objective of this research is to provide recommendations for the development of new drugs, with a particular focus on:

The design of drugs that are more selective and possess the capacity to address specific molecular targets within resistance mechanisms (Gautam, 2024).

The development of nanotechnology-based drug delivery systems with the objective of improving bioavailability and specificity.

Multidisciplinary collaboration is essential for the creation of personalised therapeutic approaches based on the patient's genetic profile, which is a key aspect of precision medicine (Ricciardi, 2023).

Providing a foundation for further research.

Furthermore, this study aims to facilitate the exploration of additional research avenues, including:

The objective of the pre-clinical studies is to evaluate the safety and effectiveness of innovative approaches.

The development of clinical trials will assess the efficacy of combination therapy and gene therapy in patients with drug resistance.

The integration of these pharmacological approaches with other technologies, such as artificial intelligence, will facilitate the development of more effective and efficient therapies.

The significance of the research objectives

This research makes a significant contribution to the fields of biomedical science and pharmacology, offering strategies that have the potential to transform the landscape of modern medicine. By supporting the development of innovative pharmacological approaches, this research is expected to reduce the global burden of drug resistance and provide direct benefits to patients.

3. Methods

This study employs a qualitative method with a descriptive-analytical approach, with the objective of exploring in depth innovative pharmacological approaches in targeting drug resistance mechanisms. Qualitative methods were selected for their capacity to facilitate a more profound comprehension of the phenomenon of drug resistance from a biomedical vantage point, while simultaneously affording the opportunity to identify and elucidate pivotal findings that could potentially give rise to innovations in drug therapy. In this study, a descriptive-analytic approach was employed to provide a comprehensive account and analysis of the diverse approaches that have been employed in addressing drug resistance, with a view to evaluating their efficacy.

Figure 1. Qualitative Method

The data employed in this study were derived from two principal sources: systematic literature reviews and in-depth interviews with experts in the field of biomedical pharmacology. A systematic literature study was conducted to collate pertinent information from a range of scientific articles published in peer-reviewed journals. The articles were selected based on rigorous inclusion criteria, which focused on pharmacological innovations related to drug resistance, as well as the relevance of the topic to the biomedical and pharmacological context. The article selection process involved searching leading journals in pharmacology, biomedicine, and health and medical sciences, taking into account the most recent publication year to ensure the most up-to-date information was obtained.

Furthermore, three experts in the field of biomedical pharmacology were interviewed in depth. The experts were selected based on their experience and expertise in dealing with drug resistance issues and innovative therapy development. The interviews were semi-structured, allowing the interviewees the flexibility to freely express their views on the latest developments in innovative pharmacological research and applications. The interview questions focused on three main aspects: (1) the most common mechanisms of drug resistance, (2) pharmacological approaches currently being developed to overcome drug resistance, and (3) challenges and future prospects in the development of new therapies.

Data Analysis

Once the data had been collected, it was subjected to a process of thematic analysis. This entailed identifying and categorising the main themes that emerged from the literature and interviews. The process began with a thorough reading and understanding of the data obtained from both scientific articles and interview transcripts. Thereafter, themes relevant to the research topic, such as the use of combination therapy, gene therapy, nanotechnology and systems-based approaches, were identified and subjected to further analysis. This was done in order to identify patterns or relationships between these approaches in addressing drug resistance.

In this thematic analysis, researchers sought to identify relationships between the various approaches that have been implemented and their effectiveness in overcoming drug resistance. Additionally, the challenges encountered in implementing these approaches, as well as the potential of emerging technologies and innovations, were examined. Data from interviews were employed to explore the perspectives of practitioners and researchers in the field, providing deeper insights into their first-hand experiences of innovative pharmacological research and applications.

Data Validity

To ensure the validity and reliability of the data, this study employed a triangulation technique, combining data from two distinct sources: a literature review and expert interviews. This triangulation enabled the researcher to verify the findings and confirm that the results were not influenced by the bias of a single data source. Furthermore, expert interviews were conducted until data saturation was reached, ensuring that the data obtained encompassed all significant aspects related to the research topic.

4. Results

The emergence of drug resistance represents a significant challenge to global health. Resistance mechanisms, including genetic mutations and biochemical alterations, impede the efficacy of treatment (Ferrara et al., 2024). Conventional monotherapy-based approaches frequently prove ineffective due to the evolution of microorganisms and cancer cells. Consequently, the development of innovative strategies targeting resistance mechanisms is imperative to enhance therapeutic outcomes.

5. Discussion

Nanotechnology in Drug Distribution: Improving Bioavailability and Overcoming Resistance

Nanotechnology is one of the innovative approaches in pharmacology that offers solutions to various challenges in medicine, including drug resistance (Epameinondas Georgakopoulou et al., 2024). With its unique ability to engineer structures at the molecular level, nanotechnology enables manipulation of drug delivery systems to make them more effective, safe and targeted. The following is a comprehensive look at how nanoparticles are being used to improve drug bioavailability and overcome resistance, with a focus on the use of liposomes in cancer therapy (Almurisi et al., 2024).



Figure 2 . Nanoemulsifying drug delivery system
(Source: (Almurisi et al., 2024).

Nanotechnology refers to the use of nanometre-scale particles (1-100 nm) to carry and deliver drug molecules to specific targets. These systems are designed to:

- Protect the drug from degradation in the body's environment (such as enzymes or gastric pH).

- Extend the half-life of the drug in the bloodstream.
- Target specific tissues specifically, thereby reducing side effects on healthy tissues.
- Overcome resistance mechanisms, such as drug effusion by transport proteins, by efficiently penetrating the cell membrane (Kale, 2023).

Drug bioavailability, i.e. the fraction of a drug that reaches the systemic circulation in its active form, is often low in conventional formulations. Factors such as first-pass metabolism in the liver and drug insolubility are major obstacles. Nanoparticles offer several solutions:

- Increasing drug solubility: Hydrophobic drugs that are poorly soluble in water can be enveloped by hydrophilic nanoparticles, such as polymers or liposomes.
- Protection against metabolism: Nanoparticles can protect drug molecules from enzymatic degradation or acidic pH in the gastrointestinal tract.
- Targeted delivery: By coating nanoparticles with specific ligands, such as antibodies or peptides, nanoparticles can be directed to receptors on target cells, such as receptors on cancer cells (Gowda et al., 2022).

Drug resistance often results from an effusion mechanism, which is the removal of drugs from the cell by transport proteins such as P-glycoprotein (P-gp). This is common in cancer cells and antibiotic-resistant microorganisms. Nanotechnology offers several solutions:

- Inhibiting effusion proteins: Nanoparticles can be modified to inhibit the activity of proteins such as P-gp, thereby increasing the accumulation of drugs inside the cell.
- Direct delivery to the cytoplasm: Some nanoparticles, such as dendrimers or lipid-based nanoparticles, can penetrate the cell membrane without being affected by effusion mechanisms.
- Penetration into hard-to-reach tissues: For example, nanoparticle systems allow drugs to cross the blood-brain barrier, which was previously a significant barrier in the treatment of brain tumours (Guo et al., 2024).

Liposomes in Cancer Therapy. Liposomes are spherical vesicles consisting of a lipid bilayer surrounding a hydrophilic core. This technology has been widely used in cancer therapy to enhance the effectiveness of chemotherapy drugs.

Liposome Mechanism of Action. Liposomes can take advantage of leaking blood vessels in tumours to enter cancerous tissues. By coating liposomes with molecules such as folate or antibodies, liposomes can bind to specific receptors on cancer cells.

Liposomes can be designed to release drugs slowly or only in certain environments, such as the acidic pH in the tumour microenvironment (Pandey et al., 2024).

Examples of Liposome-Based Drugs such as Doxil (liposomal doxorubicin). This drug is designed to reduce the cardiovascular toxicity of conventional doxorubicin by delivering the drug directly to the tumour.

Myocet, this liposomal system is used to reduce side effects in breast cancer therapy.

Liposomes are able to overcome resistance through:

- Avoiding recognition by effusion proteins.

- Altering the pharmacokinetic distribution of the drug, thereby increasing the local concentration in the tumour (Fisher et al., 2024).

Although promising, the application of nanotechnology in drug distribution faces challenges such as:

- Large-scale production: The precise production process of nanoparticles is costly.
- Biocompatibility: Some nanoparticles may trigger immune responses or toxicity.
- Regulatory and clinical approval: Complex nanotechnologies require extensive clinical trials to gain approval from regulatory bodies such as the FDA (Araujo-Filho & Meneses do Rêgo, 2024).

However, technological developments continue to open up new opportunities, such as:

- Use of biodegradable materials: Such as natural polymers (chitosan) to improve safety.
- Integration with gene therapy: Nanotechnology can be used to deliver CRISPR-Cas9 to specific targets.
- Use of artificial intelligence (AI): To design nanoparticles that more efficiently target specific tissues (Dilsiz, 2024).

Combination Therapy to Overcome Drug Resistance: A Multimodal Approach in Pharmacology

Combination therapy is a therapeutic approach that utilises two or more pharmacological agents to work synergistically to treat diseases, including those involving drug resistance mechanisms. Drug resistance occurs when microorganisms or target cells are able to adapt strategies to survive a single therapeutic attack, such as actively excreting the drug, altering the molecular target of the drug, or activating compensatory pathways. Combination therapies aim to inhibit or reverse this resistance by targeting different aspects of the resistance mechanism simultaneously. This approach offers several advantages over monotherapy:

- Synergistic Effects. Drug combinations can produce effects that are greater than the sum of the effects of each drug individually. For example, antibiotics combined with drug effusion inhibitors can inhibit bacterial resistance mechanisms and increase sensitivity to antibiotics.
- Reduction of Resistance Risk. By attacking different molecular targets, combination therapy can prevent adaptation of microorganisms or cancer cells, as they have to develop multiple resistance mechanisms at once, which is biologically more difficult.
- Decreased Dosage and Side Effects. Using lower doses of each drug in combination can reduce toxicity and side effects compared to high-dose monotherapy (Giri et al., 2024).



Figure 3. A schematic illustration depicting the effects of cancer and various treatments on patient outcomes
(Source: (Giri et al., 2024).

Examples of Effective Combination Therapy

- Antibiotics and Drug Effusion Inhibitors. Many resistant bacteria, such as Pseudomonas aeruginosa and Escherichia coli, use effusion pumps to remove antibiotics from their cells. The combination of antibiotics, such as cephalosporins, with effusion inhibitors (e.g., phenylalanine arginine β-naphthylamide) can inhibit effusion pump activity, thereby increasing intracellular antibiotic concentrations and treatment effectiveness.
- HIV Therapy with Antiretrovirals. HIV treatment uses a combination of three or more antiretroviral drugs, such as protease inhibitors, reverse transcriptase inhibitors, and integrase strand transfer inhibitors. This approach attacks the virus at different stages of its replication cycle, reducing the risk of resistance and slowing disease progression.
- Cancer Therapy. Combination chemotherapy is often used to overcome drug resistance in cancer treatment. For example, the combination of doxorubicin with paclitaxel works by attacking the DNA and disrupting the microtubules of cancer cells simultaneously.
- Malaria treatment. Resistance to antimalarial monotherapies, such as chloroquine, has led to the development of artemisinin-based combination therapy (ACT). This combination reduces the chances of Plasmodium developing resistance as it works through multiple mechanisms (De Los Santos et al., 2024).

Combination therapies are designed to work through several mechanisms, such as:

- Targeting Different Biochemical Pathways. For example, a combination of drugs can inhibit cellular energy metabolism while blocking DNA synthesis.
- Disrupting Resistance Adaptation. By combining drugs that target both effusion mechanisms and protein synthesis, microorganisms do not have enough time to develop multiple resistance.
- Microecosystem Modulation. Some combinations work by modifying the microbial environment, such as local pH reduction or inhibition of biofilm formation, thereby increasing therapeutic effectiveness (Patel et al., 2024).

Despite its promise, combination therapy has its challenges, including:

- Drug Interactions. Some drug combinations may produce unwanted antagonistic effects or toxicity. Therefore, comprehensive pre-clinical trials are required to ensure compatibility.
- Cost of Development. Drug combination development is often more expensive and requires more complex clinical trials than monotherapy.
- Monitoring Patient Compliance. Combination therapy often involves more complex treatment regimens, which may reduce patient compliance.

Inhibitor Specific Resistance Mechanism

Innovative pharmacological approaches using specific inhibitors to target mechanisms of drug resistance have become a major focus in biomedical research, particularly in cancer and chronic infections. Small molecules designed to inhibit specific proteins, such as kinases, have proven their effectiveness in overcoming resistance to conventional therapies. The following is a detailed description of the working principles, applications, and recent developments related to resistance mechanism-specific inhibitors (Yaari et al., 2024).

Drug resistance in the context of cancer and infection often involves changes in target proteins, such as genetic mutations or overexpression. Protein kinases, for example, play an important role in various cellular processes, including cell proliferation, differentiation and survival. In many cancer cases, mutations in kinase genes, such as BCR-ABL in chronic myeloid leukaemia (CML) or EGFR in lung cancer, lead to constitutive activation that supports tumour growth. Specific inhibitors work by:

- Binding directly to the active site of the target protein thereby inhibiting its biological function.
- Inducing allosteric changes to disrupt protein interactions with substrates or cofactors.
- Suppressing molecular signalling pathways regulated by the target protein, thus restoring normal cellular responses (Ovilla-Martínez et al., 2023).

Application Examples

1. Tyrosine Kinase Inhibitors (TKIs). TKIs are examples of small molecule inhibitors that have been very successful in cancer therapy.
   - Imatinib (Gleevec). Imatinib targets the BCR-ABL kinase that results from a chromosomal translocation (Philadelphia chromosome) in CML patients. This molecule binds to the ATP site on BCR-ABL, inhibits its kinase activity, and stops cancer cell proliferation.
     - Clinical success: Imatinib became the first-line therapy for CML, changing the prognosis of the disease from fatal to manageable.

- Constraints: Secondary mutations in BCR-ABL led to resistance to Imatinib, prompting the development of second-generation inhibitors, such as Dasatinib and Nilotinib.

- Erlotinib and Gefitinib. These inhibitors target EGFR (Epidermal Growth Factor Receptor) in non-small cell lung cancer (NSCLC). Mutations in EGFR often lead to constitutive activation, and these inhibitors bind to the active site of EGFR to inhibit tumour proliferation signals (Frumento et al., 2024).

2. MEK Inhibitors. MEK1/2 are kinases that play a role in the MAPK/ERK pathway, an important pathway for cell proliferation and survival.
   Trametinib. Used in melanoma with BRAF V600E mutation, this inhibitor blocks the MEK pathway, suppressing tumour growth (Mukherjee et al., 2024).
3. ALK Inhibitors. Rearrangement in ALK (Anaplastic Lymphoma Kinase) is often found in NSCLC patients.
   Crizotinib. Inhibits the activity of ALK fusions, such as EML4-ALK, and has proven effective in overcoming drug resistance due to mutations in EGFR (Chuang et al., 2021).

Many small molecule inhibitors have shown success in clinical trials, both as single therapy and in combination:

- Improved clinical response: Patients with specific mutations, such as EGFR T790M in NSCLC, showed a significant response to osimertinib, a third-generation inhibitor designed to overcome resistance to first-generation TKIs.
- Low toxicity profile: Small molecules tend to have high selectivity, so side effects on healthy tissues can be minimised.

Gene Therapy: Opening New Opportunities in Overcoming Drug Resistance.

Gene therapy is an innovative medical approach that aims to treat or prevent disease by genetically modifying the patient's body. In the context of drug resistance, gene therapy offers a tremendous opportunity to target the root cause of resistance at the molecular level. The technique works by introducing, deleting, or modifying genetic material to influence biochemical pathways associated with drug resistance. This approach has come a long way thanks to technologies such as CRISPR-Cas9 and RNA interference (RNAi) (Ming-Kun et al., 2024).

CRISPR-Cas9: A Revolutionary Tool in Genetic Editing. CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a gene editing technology that utilises the immune system of bacteria to cut DNA at specific locations. In this system:

- CRISPR Guide RNA (gRNA): Serves as a guide to recognise the target DNA sequence.
- Cas9 Nuclease: Cuts the DNA at the location targeted by the gRNA. Utilising this system, scientists can with great precision modify genes that play a role in drug resistance, either by cutting out the genes that cause resistance or replacing them with normally functioning genes.

Applications in Overcoming Drug Resistance

- Antibiotic Resistance: CRISPR-Cas9 is used to remove plasmid genes that carry antibiotic resistance, making microorganisms sensitive to drugs again.

- Cancer: Mutations in genes, such as TP53 or KRAS, are often involved in chemotherapy resistance. CRISPR can be used to correct these mutations or inactivate genes that cause resistance.
- HIV/AIDS: CRISPR has been used to delete the CCR5 gene, which allows HIV to infect cells, thus providing protection against the virus (Allemailem et al., 2024).



Figure 4. The visual depiction illustrating the causes of antibiotic resistance and the effectiveness of CRISPR/Cas9
Source: Allemailem et al., 2024).

The advantages of CRISPR include high precision, efficiency and relatively low cost compared to other technologies. However, major challenges include potential off-target effects (unintended gene modification) and immune response to Cas9, which need to be resolved before large-scale clinical application.

RNA Interference (RNAi): Controlling the Expression of Genes Contributing to Resistance. RNA interference (RNAi) is a natural mechanism of cells to control gene expression. RNAi works through two main molecules:

- siRNA (Small Interfering RNA): A short RNA molecule that pairs with a target mRNA and causes degradation of that mRNA, thus preventing protein production.
- miRNA (MicroRNA): Small RNA molecules that control gene expression by suppressing the translation of target mRNAs (Kanbar et al., 2024).

In therapy, RNAi is used to stop the expression of genes that contribute to drug resistance, such as genes that produce effusion proteins (which pump drugs out of cells) or drug detoxification enzymes.

RNAi Applications in Drug Resistance

- Cancer: RNAi has been used to suppress the expression of ABCB1, a gene that produces P-gp proteins that pump drugs out of cancer cells, increasing the effectiveness of chemotherapy.
- Viral Infections: RNAi is used to target viral genes, such as NS3 in the Hepatitis C virus, to inhibit viral replication.
- Genetic Diseases: In cystic fibrosis, RNAi is used to suppress CFTR gene mutations that cause resistance to therapy.

RNAi offers the advantage that it can be quickly customised to target various genes and has a lower risk of off-target effects compared to CRISPR. However, key challenges include the stability of the RNA molecule, effective delivery to target cells, and possible immune responses to foreign RNA molecules (Pérez-Arques et al., 2024).

The Role of Gene Therapy in Precision Medicine

- Precision medicine is a medical approach that is customised to an individual's genetic profile. In the context of drug resistance, gene therapy makes it possible:
- Identification of Specific Targets: With technologies such as CRISPR and RNAi, specific genes or molecular pathways that cause resistance can be identified and modified.
- Personalised Therapy: The patient's genetic profile is used to design the optimal therapy, reducing the risk of resistance developing further.
- Reduction of Side Effects: By targeting only relevant genes, gene therapy can minimise damage to normal tissues.

References

Allemailem, K., Almatroudi, A., Rahmani, A., Alrumaihi, F., Alradhi, A., Alsubaiyel, A., Algahtani, M., Almousa, R., Mahzari, A., Sindi, A., Dobie, G., & Khan, A. (2024). Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies. *International Journal of Nanomedicine*, *Volume 19*, 5335–5363. https://doi.org/10.2147/IJN.S455574

Almurisi, S. H., En, G. W., Hafiq, M. Z., Sheng, L. K., Sri, P., Mazlan, N. A. B. A., Bhatnagar, P., & Madheswaran, T. (2024). Review of Lipid Nanoparticles for Breast Cancer Management: Targeting Strategies and Clinical Perspective. *Current Nanomedicine, 15.* https://doi.org/10.2174/0124681873326272241011161315

Araujo-Filho, I., & Meneses do Rêgo, A. C. (2024). Nanotechnology and Immunetherapy: reduction of hepatotoxicity and anti-antineoplastic efficiency. *JOURNAL OF SURGICAL AND CLINICAL RESEARCH*, *15*(1), 59–78. https://doi.org/10.20398/jscr.v15i1.35647

Chen, E. Y., Rai, M., Tadikonda, Y., Roy, P., Nollner, D. W., Chitkara, A., Hamilton, J., & Thawani, R. (2024). Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration. *The Oncologist*. https://doi.org/10.1093/oncolo/oyae302

Chuang, C.-H., Chen, H.-L., Chang, H.-M., Tsai, Y.-C., Wu, K.-L., Chen, I.-H., Chen, K.-C., Lee, J.-Y., Chang, Y.-C., Chen, C.-L., Tu, Y.-K., Hung, J.-Y., Yang, C.-J., & Chong, I.-W. (2021). Systematic Review and

Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. *Cancers*, *13*(8), 1966. https://doi.org/10.3390/cancers13081966

Cummings, J. L., Osse, A. M. L., Kinney, J. W., Cammann, D., & Chen, J. (2024). Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. *CNS Drugs*, *38*(8), 613–624. https://doi.org/10.1007/s40263-024-01103-1

De Los Santos, M. A. I. C., Gloege, H. F., Shen, M., Heaslip, C. O., Aguilar-Quintero, A., McDannel, B., Tanhaemami, M., Meyer, S., Klega, K., Zhang, Y.-Q., Shulman, D. S., DuBois, S. G., Hall, M., Blandin, A.-F., & Crompton, B. D. (2024). *A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcoma*. https://doi.org/10.1101/2024.10.14.618327

Dilsiz, N. (2024). CRISPR-Cas9: Revolutionizing Gene Therapy for Genetic Disorders. *Pakistan BioMedical Journal*, 01. https://doi.org/10.54393/pbmj.v7i10.1166

Epameinondas Georgakopoulou, V., Papalexis, P., & Trakas, N. (2024). Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections. *Journal of Biological Methods*, *11*(4), e99010032. https://doi.org/10.14440/jbm.2024.0065

Ferrara, F., Castagna, T., Pantolini, B., Campanardi, M. C., Roperti, M., Grotto, A., Fattori, M., Dal Maso, L., Carrara, F., Zambarbieri, G., Zovi, A., Capuozzo, M., & Langella, R. (2024). The challenge of antimicrobial resistance (AMR): current status and future prospects. *Naunyn-Schmiedeberg's Archives of Pharmacology*. https://doi.org/10.1007/s00210-024-03318-x

Fisher, W. S., Douglas, J., Roshan, S., Perez, R., Wei, S., Roberts, L., Ewert, K. K., & Safinya, C. R. (2024). *Acidic Conditions Promote Clustering of Cancer Cell Derived Extracellular Vesicles and Enhance their Fusion with Synthetic Liposomes*. https://doi.org/10.1101/2024.11.04.621963

Frumento, D., Grossi, G., Falesiedi, M., Musumeci, F., Carbone, A., & Schenone, S. (2024). Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment. *International Journal of Molecular Sciences*, *25*(3), 1398. https://doi.org/10.3390/ijms25031398

Gautam, D. P. K. (2024). Plant-Derived Nanoparticles: A Green Approach for Drug Delivery Systems. *Revista Electronica de Veterinaria*, 1114–1124. https://doi.org/10.69980/redvet.v25i1S.1043

Giri, K. R., Palandurkar, K., Trigunayat, A., & Giri, R. (2024). *Reverse Pharmacology: Transdisciplinary Approach of Drug Discovery from Ethnomedicine* (pp. 267–293). https://doi.org/10.1007/978-981-97-4600-2_10

Gowda, B. H. J., Ahmed, M. G., & Husain, A. (2022). Transferosomal in situ gel administered through umbilical skin tissues for improved systemic bioavailability of drugs: A novel strategy to replace conventional transdermal route. *Medical Hypotheses*, *161*, 110805. https://doi.org/10.1016/j.mehy.2022.110805

Guo, Y., Ashrafizadeh, M., Tambuwala, M. M., Ren, J., Orive, G., & Yu, G. (2024). P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators. *Drug Discovery Today*, *29*(11), 104161. https://doi.org/10.1016/j.drudis.2024.104161

Gupta, H., & Bhandari, U. (2024). Molecular Insight into Obesity-Associated Nephropathy: Clinical Implications and Possible Strategies for its Management. *Current Drug Targets*, *26*. https://doi.org/10.2174/0113894501314788241008115712

Jin, S., Lan, Z., Yang, G., Li, X., Shi, J. Q., Liu, Y., & Zhao, C. (2024). Computationally guided design and synthesis of dual-drug loaded polymeric nanoparticles for combination therapy. *Aggregate*, *5*(5). https://doi.org/10.1002/agt2.606

Jones, K. F. M., Demir, Ö., Wyllie, M. K., Grillo, M. J., Morris, C., Hirakis, S. P., Kardile, R. D., Walters, M. A., Harris, R. S., Amaro, R. E., & Harki, D. A. (2024). *Development of Allosteric Small Molecule APOBEC3B Inhibitors from In Silico Screening*. https://doi.org/10.1101/2024.04.25.591187

Kale, N. (2023). Treatment of Cancer Using Combination of Herbal and Novel Drug Delivery System. In *Bioprospecting of Tropical Medicinal Plants* (pp. 1177–1197). Springer Nature Switzerland. https://doi.org/10.1007/978-3-031-28780-0_49

Kanbar, K., El Darzi, R., & Jaalouk, D. E. (2024). Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed. *Frontiers in Genetics*, *15*. https://doi.org/10.3389/fgene.2024.1434002

Lee, H., Woo, S. M., Jang, H., Kang, M., & Kim, S.-Y. (2022). Cancer depends on fatty acids for ATP production: A possible link between cancer and obesity. *Seminars in Cancer Biology*, *86*, 347–357. https://doi.org/10.1016/j.semcancer.2022.07.005

Lee, J., Kida, K., Koh, J., Liu, H., Manyam, G. C., Gi, Y. J., Rampa, D. R., Multani, A. S., Wang, J., Jayachandran, G., Lee, D.-W., Reuben, J. M., Sahin, A., Huo, L., Tripathy, D., Im, S.-A., & Ueno, N. T. (2024). The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer. *Journal of Experimental & Clinical Cancer Research*, *43*(1), 236. https://doi.org/10.1186/s13046-024-03143-3

Li, L., & Ma, Z. (Sam). (2024). *Estimating the selection pressure of tumor growth on tumor tissue microbiomes*. https://doi.org/10.1101/2024.03.17.24304406

Litty, A. (2024). *Business Analytics Strategies for Market Integration of Advanced Nanotechnology Solutions in Healthcare*. https://doi.org/10.20944/preprints202409.1818.v1

Liu, B., Wang, Z., Gu, M., Wang, J., & Tan, J. (2024). Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review. *Translational Lung Cancer Research*, *13*(8), 2067–2081. https://doi.org/10.21037/tlcr-24-592

M, P. (2024). Targeting of Hydrolytic Enzymes on Prodrug/Anti-cancer Drugs Efficient Metabolism for Cancer Chemotherapeutics. In *Medicine and Medical Research: New Perspectives Vol. 9* (pp. 174–188). BP International. https://doi.org/10.9734/bpi/mmrnp/v9/2397

Mao, K., Liu, C., Tang, Z., Rao, Z., & Wen, J. (2024). Advances in drug resistance of osteosarcoma caused by pregnane X receptor. *Drug Metabolism Reviews*, 1–14. https://doi.org/10.1080/03602532.2024.2366948

Markalunas, E., Arnold, D., Funkhouser, A., Martin, J., Shtutman, M., Edenfield, W., & Blenda, A. (2024). Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients. *Genes*, *15*(6), 818. https://doi.org/10.3390/genes15060818

Martina, N. A., Lawrence, O. C., Elijah, U. O., Basil, U. I., & Innocent, O. C. (2024). Evaluation of First-Line Coagulation Tests in Highly Active Antiretroviral Therapy (HAART) Naïve and Treated Group of HIV Infected Subjects. *Journal of Advances in Medical and Pharmaceutical Sciences*, *26*(3), 1–8. https://doi.org/10.9734/jamps/2024/v26i3672

Ming-Kun, C., Zi-Xian, C., Mao-Ping, C., Hong, C., Zhuang-Fei, C., & Shan-Chao, Z. (2024). Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance. *Cancer Communications*, *44*(2), 205–225. https://doi.org/10.1002/cac2.12518

Mukherjee, T., Mohanty, S., Kaur, J., Das, M., Adhikary, K., Chatterjee, P., & Maiti, R. (2024). Exploring Small-Molecule Inhibitors Targeting MAPK Pathway Components: Focus on ERK, MEK1, and MEK2 Kinases in Cancer Treatment. *Chemical Biology Letters*, *11*(2), 659–659. https://doi.org/10.62110/sciencein.cbl.2024.v11.659

Ovilla-Martínez, R., Baez Islas, P. E., Alaez-Verson, C., Ramirez Muniz, N. E., Perez-Jacobo, F., Barragan-Ibañez, G., González, M., Lopez Valles, J. M. L., Banda-García, L. I., Reynoso, E. E., Campos Cabrera, G., Perez-Lozano, U., Tingen Velarde, S., Lugo-García, Y., Reynoso, A. C., Alvarez, J. L., Severino-Lugo, H. U., & Barranco Lampón, G. I. (2023). Getting to Know the Molecular Landscape of R/R Chronic Myeloid Leukemia: NGS-Based Profiling of Myeloid Mutations Beyond BCR/ABL. *Blood*, *142*(Supplement 1), 6361–6361. https://doi.org/10.1182/blood-2023-181162

Pandey, P., Arya, D. K., Deepak, P., Ali, D., Alarifi, S., Srivastava, S., Lavasanifar, A., & Rajinikanth, P. S. (2024). αvβ3 Integrin and Folate-Targeted pH-Sensitive Liposomes with Dual Ligand Modification for Metastatic Breast Cancer Treatment. *Bioengineering*, *11*(8), 800. https://doi.org/10.3390/bioengineering11080800

Patel, A. A., Shakir, M. K., Tuamokumo, F., Bianco, A. C., & Hoang, T. D. (2024). 7445 The Effect of Combination Thyroid Hormone Therapies on Symptoms in Patients with a Suboptimal Response to Levothyroxine: A Post-Hoc Analysis. *Journal of the Endocrine Society*, *8*(Supplement_1). https://doi.org/10.1210/jendso/bvae163.2084

Pemathilaka, R. L., Alimoradi, N., Reynolds, D. E., & Hashemi, N. N. (2022). Transport of Maternally Administered Pharmaceutical Agents Across the Placental Barrier In Vitro. *ACS Applied Bio Materials*, *5*(5), 2273–2284. https://doi.org/10.1021/acsabm.2c00121

Pérez-Arques, C., Navarro-Mendoza, M. I., Xu, Z., Walther, G., & Heitman, J. (2024). *RNAi epimutations conferring antifungal drug resistance are inheritable*. https://doi.org/10.1101/2024.10.15.618540

Queffeulou, M., Leprohon, P., Fernandez-Prada, C., Ouellette, M., & Mejía-Jaramillo, A. M. (2024). CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum. *MBio*, *15*(7). https://doi.org/10.1128/mbio.00477-24

RAVAL, D., RATHOD, V., RAMNANI, J., PATHAK, D., SINGLA, A., YOUNG, M., & BHATTACHARYA, A. (2024). ASSESSMENT OF ANTIBIOTIC RESISTANCE PATTERNS AMONG BACTERIA ISOLATED FROM ENDOTRACHEAL SECRETIONS IN MECHANICALLY VENTILATED PATIENTS: A PROSPECTIVE ANALYSIS. *CHEST*, *166*(4), A2181–A2182. https://doi.org/10.1016/j.chest.2024.06.1344

Ricciardi, W. (2023). IC2PERMED: Fostering collaboration between Europe and China to enhance personalised medicine. *Open Access Government*, *39*(1), 20–21. https://doi.org/10.56367/OAG-039-10826

Roszkowska, M. (2024). Multilevel Mechanisms of Cancer Drug Resistance. *International Journal of Molecular Sciences*, *25*(22), 12402. https://doi.org/10.3390/ijms252212402

Trauner, A., Borrell, S., Reither, K., & Gagneux, S. (2014). Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and Therapy. *Drugs*, *74*(10), 1063–1072. https://doi.org/10.1007/s40265-014-0248-y

Yaari, A., Farias, E., Guedes, F., Priebe, O., McDaniel, L., Earnest, T., Ideker, T., & Sherman, M. A. (2024). Abstract 3287: Learning to target CDK4/6 inhibitor resistance via a breast cancer-specific atlas of cellular mechanisms. *Cancer Research*, *84*(6_Supplement), 3287–3287. https://doi.org/10.1158/1538-7445.AM2024-3287

Ye, Q., & Sun, Y. (2024). Graph neural pre-training based drug-target affinity prediction. *Frontiers in Genetics*, *15*. https://doi.org/10.3389/fgene.2024.1452339